Skip to main content

The Preliminary Results of the PRODIGY Study

The Preliminary Results of the PRODIGY Study

Preliminary results from the PRODIGY study were presented at the Society for Critical Care Medicine’s conference and received SCCM’s Star Award for outstanding research. Final analysis of the data showed that 46% of the 1496 hospitalized surgical/medical general care floor patients receiving opioids had one or more episodes of significant abnormalities in end-tidal CO2, SpO2, or respiratory rate lasting 3 minutes or longer, or apneas greater than 30 seconds. Monitor data was reviewed by a 4-physician expert panel for confirmation to remove potential monitor artifact.1

In addition, investigators created an easy-to-use risk prediction tool which identifies patients at higher risk who are most likely to benefit from continuous monitoring.1

View the PRODIGY study preliminary results, or and take a look at additional information and resources about the PRODIGY study, including videos, summaries, and more.

Would you like updates on Respiratory Compromise sent directly to your inbox? Subscribe today.

TOPIC: Respiratory Compromise


1. Khanna A, Buhre W, Saager L, Di Stefano P, Weingarten T, Dahan A, Brazzi L, Overdyk F. Derivation and Validation of a Novel Opioid Induced Respiratory Depression Risk Prediction Tool. Society for Critical Care Medicine 2019 conference abstract and presentation.

© 2019 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. All other brands are trademarks of a Medtronic company. 02/2019–19-PM-0003a

About the Author

Greg Spratt BS RRT CPFT is a respiratory therapist and former Director of Market Development at Medtronic. Greg has over 25 years’ clinical experience working with respiratory compromise across the healthcare continuum, has published articles in numerous pulmonary journals and periodicals, and presented internationally on improving solutions for patients with breath difficulties.

Profile Photo of Greg Spratt